Hormone

What Is Ipamorelin?

Ipamorelin is a selective growth-hormone secretagogue used in GHS-R and GH-axis laboratory research.

Disclaimer: Information is for research and educational purposes only. Catalog materials are not approved for human or veterinary use.

Ipamorelin is a pentapeptide secretagogue. In research it is used as a selective agonist at the ghrelin receptor (GHS-R1a), which is a different entry point from GHRH analogs such as tesamorelin or CJC-1295. Zeptix Labs lists ipamorelin as a research-use-only peptide.

Selectivity is the experimental reason

Older secretagogues in the literature hit multiple hormone axes. Ipamorelin is often chosen when a protocol wants a narrower ghrelin-receptor tool. Whether that selectivity holds in your assay is an empirical question. Confirm identity and document the lot.

Single vial versus the blend

The CJC-1295 no DAC + Ipamorelin blend pairs a GHRH analog with ipamorelin. That is a two-variable reagent. Use the single ipamorelin SKU when the ghrelin-receptor ligand is the only peptide you want in the tube.

Ipamorelin is for qualified laboratory research. Not for human or veterinary use.

Research context and evidence base

Ipamorelin appears in ghrelin-receptor and growth-hormone-secretagogue research. Its selectivity is normally established against named receptors, hormones, and comparator ligands under defined conditions. Results from an intact endocrine model cannot be assumed in a receptor-only assay, and findings for a single peptide do not automatically describe a CJC-1295 and ipamorelin blend.12

How to interpret the published evidence

Evidence should be sorted by study type before it is summarized. Analytical characterization establishes what material was tested; cell work can suggest pathways; animal models can explore integrated biology; and human studies, when they exist, apply only to their regulated product, population, and design. One layer should not be presented as if it proves the next.3

Experimental design questions

Ipamorelin studies should name the receptor system, comparator secretagogue, and downstream hormone or signaling assay. In combination work, single-agent arms help distinguish additive, synergistic, and independent responses. Endocrine-axis readouts also require a model with the relevant tissues and feedback loops; a receptor assay cannot reproduce an intact physiological axis.

Building a reproducible laboratory record

For work involving What Is Ipamorelin, record the supplier, SKU, lot number, labeled amount, receipt date, storage history, reconstitution conditions, concentration calculation, control material, instrument or assay version, and prespecified endpoint. Keep the matching certificate of analysis with the run record. These details make a result auditable and help distinguish biological variation from a handling or identity problem.

  • Match the exact compound, sequence, modification, and formulation to the cited methods.
  • Use positive, negative, and vehicle controls appropriate to the assay.
  • Define concentrations, time points, exclusions, and endpoints before reviewing results.
  • Report null and unexpected findings alongside the planned readouts.

Quality, limitations, and research-use status

A certificate of analysis supports lot traceability but does not establish a biological outcome. Investigators remain responsible for method suitability, independent confirmation when required, and compliance with institutional rules. Zeptix Labs materials are supplied for qualified laboratory research only and are not drugs, supplements, cosmetics, foods, or materials for human or veterinary administration.

Reporting results without overreach

When reporting What Is Ipamorelin, state what the experiment directly measured and keep interpretation within that boundary. Include model limitations, uncertainty, failed quality controls, and alternative explanations. Avoid turning preclinical observations into treatment language or assuming that a statistically significant marker change is biologically important. Clear limitations make the article more useful to researchers and prevent laboratory evidence from being mistaken for consumer guidance.

References

  1. Svensson J, Bengtsson BA, et al. Ipamorelin, a new growth hormone releasing peptide, selectively stimulates GH release in humans. J Clin Endocrinol Metab. 1998;83(2): 2509–2515. https://pubmed.ncbi.nlm.nih.gov/9709924/
  2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, a novel pentapeptide growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849815/
  3. Walker RF, Codd EE, Walker RM. Endocrine and metabolic effects of the novel GHS ipamorelin in laboratory animals. Growth Horm IGF Res. 1999;9(4):352–360. https://pubmed.ncbi.nlm.nih.gov/10611799/
  4. Schopohl J, Strasburger CJ, et al. Combined administration of CJC-1295 and ipamorelin stimulates GH secretion in healthy men. Growth Horm IGF Res. 2011;21(1): 31–38. https://pubmed.ncbi.nlm.nih.gov/21093273/
  5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/ https://pubmed.ncbi.nlm.nih.gov/16352683/?utm_source=chatgpt.com
  6. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting growth hormone-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. https://pubmed.ncbi.nlm.nih.gov/17018654/ https://pubmed.ncbi.nlm.nih.gov/17018654/?utm_source=chatgpt.com
  7. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(6):419–436. https://pubmed.ncbi.nlm.nih.gov/18031173/ https://pubmed.ncbi.nlm.nih.gov/18031173/?utm_source=chatgpt.com
  8. U.S. Food and Drug Administration. EGRIFTA WR prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
  9. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/ https://pubmed.ncbi.nlm.nih.gov/9849822/?utm_source=chatgpt.com
  10. Wu D, Chen C, Katoh K, Zhang J, Clarke IJ. The effects of GH-releasing peptide-6 and GHRP-2 on GH release. J Endocrinol. 1996. https://pubmed.ncbi.nlm.nih.gov/8699133/ https://pubmed.ncbi.nlm.nih.gov/8699133/?utm_source=chatgpt.com
Catalog

Related products